Rezolute (NASDAQ:RZLT) Share Price Breaks Below 200 Day Moving Average – Should You Sell?

Rezolute, Inc. (NASDAQ:RZLT – Get Free Report)’s stock price passed below its 200-day moving average during trading on Friday. The stock has a 200-day moving average of $3.94 and traded as low as $3.86. Rezolute shares last traded at $3.92, with a volume of 2,474,500 shares traded.

Analysts Set New Price Targets

A number of brokerages have weighed in on RZLT. Lake Street Capital boosted their price objective on Rezolute from $9.00 to $12.00 and gave the company a “buy” rating in a research note on Tuesday, October 6th. Citizens Jmp raised their target price on shares of Rezolute from $11.00 to $15.00 and gave the stock a “market outperform” rating in a research report on Tuesday, October 6th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Rezolute in a report on Thursday, October 15th. Cantor Fitzgerald raised shares of Rezolute from a “neutral” rating to an “overweight” rating in a report on Monday, October 5th. Finally, Wedbush upped their price target on shares of Rezolute from $6.00 to $10.00 and gave the company an “outperform” rating in a research report on Tuesday, November 17th. Twelve analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $11.67.

Check Out Our Latest Stock Report on Rezolute

Rezolute Stock Performance

The company has a 50-day moving average of $4.04 and a 200-day moving average of $3.94. The stock has a market cap of $379.18 million, a price-to-earnings ratio of -5.16 and a beta of 0.65.

Rezolute (NASDAQ:RZLT – Get Free Report) last posted its quarterly earnings data on Thursday, November 5th. The company reported ($0.18) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.19) by $0.01. As a group, equities research analysts forecast that Rezolute, Inc. will post -0.66 EPS for the current year.

Institutional Investors Weigh In On Rezolute

A number of institutional investors have recently added to or reduced their stakes in the business. Auxano Advisors LLC acquired a new position in Rezolute during the 2nd quarter worth approximately $52,000. Sequoia Financial Advisors LLC acquired a new stake in shares of Rezolute in the 2nd quarter valued at approximately $75,000. WINTON GROUP Ltd purchased a new stake in shares of Rezolute in the second quarter valued at approximately $88,000. Hsbc Holdings PLC boosted its stake in shares of Rezolute by 189.4% in the first quarter. Hsbc Holdings PLC now owns 36,939 shares of the company’s stock valued at $113,000 after buying an additional 24,177 shares in the last quarter. Finally, American Century Companies Inc. boosted its stake in shares of Rezolute by 33.3% in the third quarter. American Century Companies Inc. now owns 33,330 shares of the company’s stock valued at $138,000 after buying an additional 8,333 shares in the last quarter. Hedge funds and other institutional investors own 82.97% of the company’s stock.

About Rezolute

(Get Free Report)

Rezolute, Inc. is a clinical-stage biopharmaceutical company based in Redwood City, California. It develops treatments for rare diseases, with a focus on conditions that cause dangerously low blood sugar. The company’s lead drug candidate, ersodetug (formerly RZ358), is an investigational monoclonal antibody designed to modulate insulin-receptor signaling. Rezolute is studying it for congenital hyperinsulinism, a rare disorder in which the body produces too much insulin, and other forms of severe hypoglycemia.

Further Reading

Receive News & Ratings for Rezolute Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rezolute and related companies with MarketBeat.com's FREE daily email newsletter.